Takeda Launches Three New Diabetes Treatments

KAZANO (alogliptin/metformin HCl), NESINA (alogliptin), OSENI (alogliptin/pioglitazone) Tablets
KAZANO (alogliptin/metformin HCl), NESINA (alogliptin), OSENI (alogliptin/pioglitazone) Tablets

Takeda announced the availability of Nesina (alogliptin), Kazano (alogliptin and metformin HCl), and Oseni (alogliptin and pioglitazone). These three agents were approved in January 2013 as adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

RELATED: Antidiabetic Monographs

Nesina is a dipeptidyl peptidase-4 inhibitor (DPP-4i) that slows the inactivation of incretin hormones GLP-1 and GIP. Kazano combines alogliptin with metformin HCl, a biguanide antidiabetic, in a single tablet. Oseni combines alogliptin with pioglitazone, a thiazolidinedione (TZD) – the first product to include both a DPP-4i and TZD in a single tablet.

Nesina is available in 6.25mg (30-, 90-, 500-count), 12.5mg (30-, 90-, 500-count), and 25mg (30- and 90-count) strength tablets. Kazano is available in 12.5mg/500mg and 12.5mg/1000mg tablets in 60-, 180-, and 500-count bottles. Oseni is available in 25mg/15mg, 25mg/30mg, 25mg/45mg, 12.5mg/15mg, 12.5mg/30mg, and 12.5mg/45mg tablets in 30-, 90-, and 500-count bottles.

For more information call (877) 825-3327 or visit Takeda.us